OUI THERAPEUTICS INC — Department of Health and Human Services SBIR Phase I: 104

Description

ABSTRACT Suicide is a top two cause of death in the US for adolescents and suicide rates among youth have steadily increased. Despite this, there is a paucity of research on mobile technology designed to reduce suicide attempts among youth. In this Phase I SBIR application Oui Therapeutics, LLC proposes a project to: 1) Create a beta version of Aviva-Y for youth (ages 13 - 17); and 2) to test the feasibility and acceptability of the beta version of Aviva-Y in a single-group, open-label trial. Successful execution of the goals of this Phase I project will generate a version of Aviva-Y that is ready to be tested for efficacy with stabilized patients in a clinical trial. In the long term, this project will have a beneficial impact on the field of youth suicide prevention through the development of mobile technology designed to advance the delivery and dissemination of effective interventions.PROJECT NARRATIVE This project will enable Oui Therapeutics, LLC to design, build, and test mobile technology (i.e. “Aviva-Y”) designed to advance the delivery and dissemination of effective interventions for adolescent suicide prevention. The project will include beta version app development, and a feasibility study of Aviva-Y. Successful outcomes of this Phase I application will include a production version of Aviva-Y.